Skip to main content

Giant drug deal: Bristol-Myers Squibb buying Celgene for $74 billion

Bristol-Myers Squibb said the deal will strengthen its cancer and inflammatory disease drug products.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.